The kappa opioid receptor: From addiction to depression, and back

Frontiers in Psychiatry

Volumn 5, Issue DEC, 2014, Pages

  Laurence Lalanne, ^a   Gulebru Ayranci, ^a,b   Brigitte L Kieffer, ^b   Lutz, Pierre Eric ^b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

Author keywords

Addiction; Anhedonia; Animal models; Comorbidity; Depression; Kappa opioid receptor; Place conditioning; Reward

Indexed keywords

DOPAMINE; KAPPA OPIATE RECEPTOR;

ADDICTION; DEPRESSION; DISEASE ASSOCIATION; DRUG SEEKING BEHAVIOR; DYSPHORIA; EMOTIONALITY; FRONTAL CORTEX; HUMAN; LIMBIC CORTEX; MENTAL STRESS; NERVE CELL NETWORK; NEUROCHEMISTRY; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; RELAPSE; REVIEW; REWARD; SYMPTOM; VENTRAL TEGMENTUM;

EID: 84961291612     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2014.00170     Document Type: Review

References (165)

1. Volkow ND, Baler RD, Goldstein RZ. Addiction: pulling at the neural threads of social behaviors. Neuron (2011) 69(4):599-602. doi:10.1016/j.neuron.2011.01.027
2. Bakken K, Landheim AS, Vaglum P. Axis I and II disorders as long-term predictors of mental distress: a six-year prospective follow-up of substance-dependent patients. BMC Psychiatry (2007) 7:29. doi:10.1186/1471-244X-7-29
3. de Graaf R, Bijl RV, Ten Have M, Beekman AT, Vollebergh WA. Pathways to comorbidity: the transition of pure mood, anxiety and substance use disorders into comorbid conditions in a longitudinal population-based study. J Affect Disord (2004) 82(3):461-7. doi:10.1016/j.jad.2004.03.001
4. Goldstein A, Tachibana S, Lowney LI, Hunkapiller M, Hood L. Dynorphin-(1-13), an extraordinarily potent opioid peptide. Proc Natl Acad Sci U S A (1979) 76(12):6666-70. doi:10.1073/pnas.76.12.6666
5. Chavkin C, James IF, Goldstein A. Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science (1982) 215(4531):413-5. doi:10.1126/science.6120570
6. Le Merrer J, Becker JA, Befort K, Kieffer BL. Reward processing by the opioid system in the brain. Physiol Rev (2009) 89(4):1379-412. doi:10.1152/physrev.00005.2009
7. Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci (2005) 8(11):1445-9. doi:10.1038/nn1578
8. Pradhan AA, Befort K, Nozaki C, Gaveriaux-Ruff C, Kieffer BL. The delta opioid receptor: an evolving target for the treatment of brain disorders. Trends Pharmacol Sci (2011) 32(10):581-90. doi:10.1016/j.tips.2011.06.008
9. Lutz PE, Kieffer BL. The multiple facets of opioid receptor function: implications for addiction. Curr Opin Neurobiol (2013) 23(4):473-9. doi:10.1016/j.conb.2013.02.005
10. Lutz PE, Kieffer BL. Opioid receptors: distinct roles in mood disorders. Trends Neurosci (2013) 36(3):195-206. doi:10.1016/j.tins.2012.11.002
11. Charbogne P, Kieffer BL, Befort K. 15 years of genetic approaches in vivo for addiction research: opioid receptor and peptide gene knockout in mouse models of drug abuse. Neuropharmacology (2014) 76:204-17. doi:10.1016/j.neuropharm.2013.08.028
12. Chefer VI, Backman CM, Gigante ED, Shippenberg TS. Kappa opioid receptors on dopaminergic neurons are necessary for kappa-mediated place aversion. Neuropsychopharmacology (2013) 38(13):2623-31. doi:10.1038/npp.2013.171
13. Tejeda HA, Counotte DS, Oh E, Ramamoorthy S, Schultz-Kuszak KN, Backman CM, et al. Prefrontal cortical kappa-opioid receptor modulation of local neurotransmission and conditioned place aversion. Neuropsychopharmacology (2013) 38(9):1770-9. doi:10.1038/npp.2013.76
14. Bruchas MR, Schindler AG, Shankar H, Messinger DI, Miyatake M, Land BB, et al. Selective p38alpha MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction. Neuron (2011) 71(3):498-511. doi:10.1016/j.neuron.2011.06.011
15. Ahmad T, Lauzon NM, de Jaeger X, Laviolette SR. Cannabinoid transmission in the prelimbic cortex bidirectionally controls opiate reward and aversion signaling through dissociable kappa versus mu-opiate receptor dependent mechanisms. J Neurosci (2013) 33(39):15642-51. doi:10.1523/JNEUROSCI.1686-13.2013
16. Schindler AG, Messinger DI, Smith JS, Shankar H, Gustin RM, Schattauer SS, et al. Stress produces aversion and potentiates cocaine reward by releasing endogenous dynorphins in the ventral striatum to locally stimulate serotonin reuptake. J Neurosci (2012) 32(49):17582-96. doi:10.1523/JNEUROSCI.3220-12.2012
17. Bruchas MR, Land BB, Chavkin C. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res (2010) 1314:44-55. doi:10.1016/j.brainres.2009.08.062
18. Knoll AT, Carlezon WA Jr. Dynorphin, stress, and depression. Brain Res (2010) 1314:56-73. doi:10.1016/j.brainres.2009.09.074
19. Berger AL, Williams AM, McGinnis MM, Walker BM. Affective cue-induced escalation of alcohol self-administration and increased 22-kHz ultrasonic vocalizations during alcohol withdrawal: role of kappa-opioid receptors. Neuropsychopharmacology (2013) 38(4):647-54. doi:10.1038/npp.2012.229
20. Smith JS, Schindler AG, Martinelli E, Gustin RM, Bruchas MR, Chavkin C. Stress-induced activation of the dynorphin/kappa-opioid receptor system in the amygdala potentiates nicotine conditioned place preference. J Neurosci (2012) 32(4):1488-95. doi:10.1523/JNEUROSCI.2980-11.2012
21. Kallupi M, Wee S, Edwards S, Whitfield TW Jr, Oleata CS, Luu G, et al. Kappa opioid receptor-mediated dysregulation of gamma-aminobutyric acidergic transmission in the central amygdala in cocaine addiction. Biol Psychiatry (2013) 74(7):520-8. doi:10.1016/j.biopsych.2013.04.028
22. Harrison C. Trial watch: opioid receptor blocker shows promise in phase II depression trial. Nat Rev Drug Discov (2013) 12(6):415. doi:10.1038/nrd4028
23. Gerra G, Borella F, Zaimovic A, Moi G, Bussandri M, Bubici C, et al. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend (2004) 75(1):37-45. doi:10.1016/j.drugalcdep.2003.11.017
24. Gerra G, Fantoma A, Zaimovic A. Naltrexone and buprenorphine combination in the treatment of opioid dependence. J Psychopharmacol (2006) 20(6):806-14. doi:10.1177/0269881106060835
25. Pfeiffer A, Brantl V, Herz A, Emrich HM. Psychotomimesis mediated by kappa opiate receptors. Science (1986) 233(4765):774-6. doi:10.1126/science.3016896
26. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, et al. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A (2002) 99(18):11934-9. doi:10.1073/pnas.182234399
27. Shippenberg TS, Herz A. Differential effects of mu and kappa opioid systems on motivational processes. NIDA Res Monogr (1986) 75:563-6.
28. Nestler EJ, Carlezon WA Jr. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry (2006) 59(12):1151-9. doi:10.1016/j.biopsych.2005.09.018
29. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A (1988) 85(14):5274-8. doi:10.1073/pnas.85.14.5274
30. Johnson SW, North RA. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci (1992) 12(2):483-8.
31. Jalabert M, Bourdy R, Courtin J, Veinante P, Manzoni OJ, Barrot M, et al. Neuronal circuits underlying acute morphine action on dopamine neurons. Proc Natl Acad Sci U S A (2011) 108(39):16446-50. doi:10.1073/pnas.1105418108
32. Matsui A, Jarvie BC, Robinson BG, Hentges ST, Williams JT. Separate GABA afferents to dopamine neurons mediate acute action of opioids, development of tolerance, and expression of withdrawal. Neuron (2014) 82(6):1346-56. doi:10.1016/j.neuron.2014.04.030
33. Spanagel R, Herz A, Shippenberg TS. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci U S A (1992) 89(6):2046-50. doi:10.1073/pnas.89.6.2046
34. Metzger D, Chambon P. Site- and time-specific gene targeting in the mouse. Methods (2001) 24(1):71-80. doi:10.1006/meth.2001.1159
35. Backman CM, Malik N, Zhang Y, Shan L, Grinberg A, Hoffer BJ, et al. Characterization of a mouse strain expressing Cre recombinase from the 3' untranslated region of the dopamine transporter locus. Genesis (2006) 44(8):383-90. doi:10.1002/dvg.20228
36. Paterson NE, Markou A. Animal models and treatments for addiction and depression co-morbidity. Neurotox Res (2007) 11(1):1-32. doi:10.1007/BF03033479
37. Land BB, Bruchas MR, Lemos JC, Xu M, Melief EJ, Chavkin C. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. J Neurosci (2008) 28(2):407-14. doi:10.1523/JNEUROSCI.4458-07.2008
38. Land BB, Bruchas MR, Schattauer S, Giardino WJ, Aita M, Messinger D, et al. Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking. Proc Natl Acad Sci U S A (2009) 106(45):19168-73. doi:10.1073/pnas.0910705106
39. Al-Hasani R, McCall JG, Foshage AM, Bruchas MR. Locus coeruleus kappa-opioid receptors modulate reinstatement of cocaine place preference through a noradrenergic mechanism. Neuropsychopharmacology (2013) 38(12):2484-97. doi:10.1038/npp.2013.151
40. Lemos JC, Roth CA, Messinger DI, Gill HK, Phillips PE, Chavkin C. Repeated stress dysregulates kappa-opioid receptor signaling in the dorsal raphe through a p38alpha MAPK-dependent mechanism. J Neurosci (2012) 32(36):12325-36. doi:10.1523/JNEUROSCI.2053-12.2012
41. Beardsley PM, Howard JL, Shelton KL, Carroll FI. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (2005) 183(1):118-26. doi:10.1007/s00213-005-0167-4
42. Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WC Jr., et al. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther (2003) 305(1):323-30. doi:10.1124/jpet.102.046433
43. Shirayama Y, Ishida H, Iwata M, Hazama GI, Kawahara R, Duman RS. Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J Neurochem (2004) 90(5):1258-68. doi:10.1111/j.1471-4159.2004.02589.x
44. Carlezon WA Jr, Beguin C, DiNieri JA, Baumann MH, Richards MR, Todtenkopf MS, et al. Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther (2006) 316(1):440-7. doi:10.1124/jpet.105.092304
45. Falcon E, Maier K, Robinson SA, Hill-Smith TE, Lucki I. Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice. Psychopharmacology (2014). doi:10.1007/s00213-014-3723-y
46. Cohen A, Whitfield TW, Kreifeldt M, Koebel P, Kieffer BL, Contet C, et al. Virus-mediated shRNA knockdown of prodynorphin in the rat nucleus accumbens attenuates depression-like behavior and cocaine locomotor sensitization. PLoS One (2014) 9(5):e97216. doi:10.1371/journal.pone.0097216
47. Muschamp JW, Hollander JA, Thompson JL, Voren G, Hassinger LC, Onvani S, et al. Hypocretin (orexin) facilitates reward by attenuating the antireward effects of its cotransmitter dynorphin in ventral tegmental area. Proc Natl Acad Sci U S A (2014) 111(16):E1648-55. doi:10.1073/pnas.1315542111
48. Li X, Marchant NJ, Shaham Y. Opposing roles of cotransmission of dynorphin and hypocretin on reward and motivation. Proc Natl Acad Sci U S A (2014) 111(16):5765-6. doi:10.1073/pnas.1403603111
49. Bals-Kubik R, Ableitner A, Herz A, Shippenberg TS. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J Pharmacol Exp Ther (1993) 264(1):489-95.
50. Svingos AL, Chavkin C, Colago EE, Pickel VM. Major coexpression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles. Synapse (2001) 42(3):185-92. doi:10.1002/syn.10005
51. Meshul CK, McGinty JF. Kappa opioid receptor immunoreactivity in the nucleus accumbens and caudate-putamen is primarily associated with synaptic vesicles in axons. Neuroscience (2000) 96(1):91-9. doi:10.1016/S0306-4522(99)90481-5
52. Hjelmstad GO, Fields HL. Kappa opioid receptor activation in the nucleus accumbens inhibits glutamate and GABA release through different mechanisms. J Neurophysiol (2003) 89(5):2389-95. doi:10.1152/jn.01115.2002
53. Svingos AL, Colago EE. Kappa-opioid and NMDA glutamate receptors are differentially targeted within rat medial prefrontal cortex. Brain Res (2002) 946(2):262-71. doi:10.1016/S0006-8993(02)02894-9
54. Margolis EB, Hjelmstad GO, Bonci A, Fields HL. Kappa-opioid agonists directly inhibit midbrain dopaminergic neurons. J Neurosci (2003) 23(31):9981-6.
55. Margolis EB, Lock H, Chefer VI, Shippenberg TS, Hjelmstad GO, Fields HL. Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. Proc Natl Acad Sci U S A (2006) 103(8):2938-42. doi:10.1073/pnas.0511159103
56. Ekstrand MI, Nectow AR, Knight ZA, Latcha KN, Pomeranz LE, Friedman JM. Molecular profiling of neurons based on connectivity. Cell (2014) 157(5):1230-42. doi:10.1016/j.cell.2014.03.059
57. Erbs E, Faget L, Scherrer G, Matifas A, Filliol D, Vonesch JL, et al. A mu-delta opioid receptor brain atlas reveals neuronal co-occurrence in subcortical networks. Brain Struct Funct (2014). doi:10.1007/s00429-014-0717-9
58. Scherrer G, Tryoen-Toth P, Filliol D, Matifas A, Laustriat D, Cao YQ, et al. Knockin mice expressing fluorescent delta-opioid receptors uncover G protein-coupled receptor dynamics in vivo. Proc Natl Acad Sci U S A (2006) 103(25):9691-6. doi:10.1073/pnas.0603359103
59. Wee S, Koob GF. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology (2010) 210(2):121-35. doi:10.1007/s00213-010-1825-8
60. Kuzmin AV, Semenova S, Gerrits MA, Zvartau EE, Van Ree JM. Kappa-opioid receptor agonist U50,488H modulates cocaine and morphine self-administration in drug-naive rats and mice. Eur J Pharmacol (1997) 321(3):265-71. doi:10.1016/S0014-2999(96)00961-2
61. Glick SD, Maisonneuve IM, Raucci J, Archer S. Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res (1995) 681(1-2):147-52. doi:10.1016/0006-8993(95)00306-B
62. Nestby P, Schoffelmeer AN, Homberg JR, Wardeh G, De Vries TJ, Mulder AH, et al. Bremazocine reduces unrestricted free-choice ethanol self-administration in rats without affecting sucrose preference. Psychopharmacology (1999) 142(3):309-17. doi:10.1007/s002130050894
63. Lindholm S, Werme M, Brene S, Franck J. The selective kappa-opioid receptor agonist U50,488H attenuates voluntary ethanol intake in the rat. Behav Brain Res (2001) 120(2):137-46. doi:10.1016/S0166-4328(00)00368-5
64. Logrip ML, Janak PH, Ron D. Blockade of ethanol reward by the kappa opioid receptor agonist U50,488H. Alcohol (2009) 43(5):359-65. doi:10.1016/j.alcohol.2009.05.001
65. Negus SS, Mello NK, Portoghese PS, Lin CE. Effects of kappa opioids on cocaine self-administration by rhesus monkeys. J Pharmacol Exp Ther (1997) 282(1):44-55.
66. Mello NK, Negus SS. Effects of kappa opioid agonists on cocaine- and food-maintained responding by rhesus monkeys. J Pharmacol Exp Ther (1998) 286(2):812-24.
67. Schenk S, Partridge B, Shippenberg TS. Effects of the kappa-opioid receptor agonist, U69593, on the development of sensitization and on the maintenance of cocaine self-administration. Neuropsychopharmacology (2001) 24(4):441-50. doi:10.1016/S0893-133X(00)00190-1
68. Schenk S, Partridge B, Shippenberg TS. U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking. Psychopharmacology (1999) 144(4):339-46. doi:10.1007/s002130051016
69. Galeote L, Berrendero F, Bura SA, Zimmer A, Maldonado R. Prodynorphin gene disruption increases the sensitivity to nicotine self-administration in mice. Int J Neuropsychopharmacol (2009) 12(5):615-25. doi:10.1017/S1461145708009450
70. Mendizabal V, Zimmer A, Maldonado R. Involvement of kappa/dynorphin system in WIN 55,212-2 self-administration in mice. Neuropsychopharmacology (2006) 31(9):1957-66. doi:10.1038/sj.npp.1300957
71. Maisonneuve IM, Archer S, Glick SD. U50,488, a kappa opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci Lett (1994) 181(1-2):57-60. doi:10.1016/0304-3940(94)90559-2
72. Femenia T, Manzanares J. Increased ethanol intake in prodynorphin knockout mice is associated to changes in opioid receptor function and dopamine transmission. Addict Biol (2011) 17(2):322-37. doi:10.1111/j.1369-1600.2011.00378.x
73. Resendez SL, Kuhnmuench M, Krzywosinski T, Aragona BJ. Kappa-opioid receptors within the nucleus accumbens shell mediate pair bond maintenance. J Neurosci (2012) 32(20):6771-84. doi:10.1523/JNEUROSCI.5779-11.2012
74. Vanderschuren LJ, Niesink RJ, Spruijt BM, Van Ree JM. Mu- and kappa-opioid receptor-mediated opioid effects on social play in juvenile rats. Eur J Pharmacol (1995) 276(3):257-66. doi:10.1016/0014-2999(95)00040-R
75. Trezza V, Baarendse PJ, Vanderschuren LJ. The pleasures of play: pharmacological insights into social reward mechanisms. Trends Pharmacol Sci (2010) 31(10):463-9. doi:10.1016/j.tips.2010.06.008
76. Robles CF, McMackin MZ, Campi KL, Doig IE, Takahashi EY, Pride MC, et al. Effects of kappa opioid receptors on conditioned place aversion and social interaction in males and females. Behav Brain Res (2014) 262:84-93. doi:10.1016/j.bbr.2014.01.003
77. Carlezon WA Jr, Chartoff EH. Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation. Nat Protoc (2007) 2(11):2987-95. doi:10.1038/nprot.2007.441
78. Todtenkopf MS, Marcus JF, Portoghese PS, Carlezon WA Jr. Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology (2004) 172(4):463-70. doi:10.1007/s00213-003-1680-y
79. Potter DN, Damez-Werno D, Carlezon WA Jr, Cohen BM, Chartoff EH. Repeated exposure to the kappa-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity. Biol Psychiatry (2011) 70(8):744-53. doi:10.1016/j.biopsych.2011.05.021
80. Solomon RL, Corbit JD. An opponent-process theory of motivation. II Cigarette addiction. J Abnorm Psychol (1973) 81(2):158-71. doi:10.1037/h0034534
81. Koob GF, Le Moal M. Review. Neurobiological mechanisms for opponent motivational processes in addiction. Philos Trans R Soc Lond B Biol Sci (2008) 363(1507):3113-23. doi:10.1098/rstb.2008.0094
82. Thompson AC, Zapata A, Justice JB Jr, Vaughan RA, Sharpe LG, Shippenberg TS. Kappa-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine. J Neurosci (2000) 20(24):9333-40.
83. Ebner SR, Roitman MF, Potter DN, Rachlin AB, Chartoff EH. Depressive-like effects of the kappa opioid receptor agonist salvinorin A are associated with decreased phasic dopamine release in the nucleus accumbens. Psychopharmacology (2010) 210(2):241-52. doi:10.1007/s00213-010-1836-5
84. Gehrke BJ, Chefer VI, Shippenberg TS. Effects of acute and repeated administration of salvinorin A on dopamine function in the rat dorsal striatum. Psychopharmacology (2008) 197(3):509-17. doi:10.1007/s00213-007-1067-6
85. Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ. Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacology (2005) 179(3):551-8. doi:10.1177/0269881105056526
86. Muschamp JW, Van't Veer A, Parsegian A, Gallo MS, Chen M, Neve RL, et al. Activation of CREB in the nucleus accumbens shell produces anhedonia and resistance to extinction of fear in rats. J Neurosci (2011) 31(8):3095-103. doi:10.1523/JNEUROSCI.5973-10.2011
87. Russell SE, Rachlin AB, Smith KL, Muschamp J, Berry L, Zhao Z, et al. Sex differences in sensitivity to the depressive-like effects of the kappa opioid receptor agonist u-50488 in rats. Biol Psychiatry (2014) 76(3):213-22. doi:10.1016/j.biopsych.2013.07.042
88. Newton SS, Thome J, Wallace TL, Shirayama Y, Schlesinger L, Sakai N, et al. Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. J Neurosci (2002) 22(24):10883-90.
89. del Rosario Capriles N, Cancela LM. Motivational effects mu- and kappa-opioid agonists following acute and chronic restraint stress: involvement of dopamine D(1) and D(2) receptors. Behav Brain Res (2002) 132(2):159-69. doi:10.1016/S0166-4328(01)00414-4
90. McLaughlin JP, Marton-Popovici M, Chavkin C. Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci (2003) 23(13):5674-83.
91. Miczek KA, Yap JJ, Covington HE III. Social stress, therapeutics and drug abuse: preclinical models of escalated and depressed intake. Pharmacol Ther (2008) 120(2):102-28. doi:10.1016/j.pharmthera.2008.07.006
92. McLaughlin JP, Li S, Valdez J, Chavkin TA, Chavkin C. Social defeat stress-induced behavioral responses are mediated by the endogenous kappa opioid system. Neuropsychopharmacology (2006) 31(6):1241-8.
93. Krishnan V, Han MH, Graham DL, Berton O, Renthal W, Russo SJ, et al. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell (2007) 131(2):391-404. doi:10.1016/j.cell.2007.09.018
94. Berube P, Laforest S, Bhatnagar S, Drolet G. Enkephalin and dynorphin mRNA expression are associated with resilience or vulnerability to chronic social defeat stress. Physiol Behav (2013) 122:237-45. doi:10.1016/j.physbeh.2013.04.009
95. Nocjar C, Zhang J, Feng P, Panksepp J. The social defeat animal model of depression shows diminished levels of orexin in mesocortical regions of the dopamine system, and of dynorphin and orexin in the hypothalamus. Neuroscience (2012) 218:138-53. doi:10.1016/j.neuroscience.2012.05.033
96. Chaudhury D, Walsh JJ, Friedman AK, Juarez B, Ku SM, Koo JW, et al. Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons. Nature (2013) 493(7433):532-6. doi:10.1038/nature11713
97. Tao R, Auerbach SB. Opioid receptor subtypes differentially modulate serotonin efflux in the rat central nervous system. J Pharmacol Exp Ther (2002) 303(2):549-56. doi:10.1124/jpet.102.037861
98. Tao R, Auerbach SB. mu-opioids disinhibit and kappa-opioids inhibit serotonin efflux in the dorsal raphe nucleus. Brain Res (2005) 1049(1):70-9. doi:10.1016/j.brainres.2005.04.076
99. Zhang H, Shi YG, Woods JH, Watson SJ, Ko MC. Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: behavioral and BDNF mRNA expression studies. Eur J Pharmacol (2007) 570(1-3):89-96. doi:10.1016/j.ejphar.2007.05.045
100. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med (2008) 358(1):55-68. doi:10.1056/NEJMra073096
101. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology (2010) 35(1):217-38. doi:10.1038/npp.2009.110
102. Sinha R, Garcia M, Paliwal P, Kreek MJ, Rounsaville BJ. Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes. Arch Gen Psychiatry (2006) 63(3):324-31. doi:10.1001/archpsyc.63.3.324
103. Aldrich JV, Patkar KA, McLaughlin JP. Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action. Proc Natl Acad Sci U S A (2009) 106(43):18396-401. doi:10.1073/pnas.0910180106
104. Redila VA, Chavkin C. Stress-induced reinstatement of cocaine seeking is mediated by the kappa opioid system. Psychopharmacology (2008) 200(1):59-70. doi:10.1007/s00213-008-1122-y
105. McLaughlin JP, Land BB, Li S, Pintar JE, Chavkin C. Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning. Neuropsychopharmacology (2006) 31(4):787-94. doi:10.1038/sj.npp.1300860
106. Sperling RE, Gomes SM, Sypek EI, Carey AN, McLaughlin JP. Endogenous kappa-opioid mediation of stress-induced potentiation of ethanol-conditioned place preference and self-administration. Psychopharmacology (2010) 210(2):199-209. doi:10.1007/s00213-010-1844-5
107. Kreibich A, Reyes BA, Curtis AL, Ecke L, Chavkin C, Van Bockstaele EJ, et al. Presynaptic inhibition of diverse afferents to the locus ceruleus by kappa-opiate receptors: a novel mechanism for regulating the central norepinephrine system. J Neurosci (2008) 28(25):6516-25. doi:10.1523/JNEUROSCI.0390-08.2008
108. Reyes BA, Chavkin C, van Bockstaele EJ. Subcellular targeting of kappa-opioid receptors in the rat nucleus locus coeruleus. J Comp Neurol (2009) 512(3):419-31. doi:10.1002/cne.21880
109. Zhou Y, Leri F, Grella SL, Aldrich JV, Kreek MJ. Involvement of dynorphin and kappa opioid receptor in yohimbine-induced reinstatement of heroin seeking in rats. Synapse (2013) 67(6):358-61. doi:10.1002/syn.21638
110. Lutz PE. Multiple serotonergic paths to antidepressant efficacy. J Neurophysiol (2013) 109(9):2245-9. doi:10.1152/jn.01093.2012
111. McDevitt RA, Neumaier JF. Regulation of dorsal raphe nucleus function by serotonin autoreceptors: a behavioral perspective. J Chem Neuroanat (2011) 41(4):234-46. doi:10.1016/j.jchemneu.2011.05.001
112. Graziane NM, Polter AM, Briand LA, Pierce RC, Kauer JA. Kappa opioid receptors regulate stress-induced cocaine seeking and synaptic plasticity. Neuron (2013) 77(5):942-54. doi:10.1016/j.neuron.2012.12.034
113. Polter AM, Bishop RA, Briand LA, Graziane NM, Pierce RC, Kauer JA. Poststress block of kappa opioid receptors rescues long-term potentiation of inhibitory synapses and prevents reinstatement of cocaine seeking. Biol Psychiatry (2014). doi:10.1016/j.biopsych.2014.04.019
114. Sivam SP. Cocaine selectively increases striatonigral dynorphin levels by a dopaminergic mechanism. J Pharmacol Exp Ther (1989) 250(3):818-24.
115. Solecki W, Ziolkowska B, Krowka T, Gieryk A, Filip M, Przewlocki R. Alterations of prodynorphin gene expression in the rat mesocorticolimbic system during heroin self-administration. Brain Res (2009) 1255:113-21. doi:10.1016/j.brainres.2008.12.002
116. Przewlocka B, Turchan J, Lason W, Przewlocki R. Ethanol withdrawal enhances the prodynorphin system activity in the rat nucleus accumbens. Neurosci Lett (1997) 238(1-2):13-6. doi:10.1016/S0304-3940(97)00829-X
117. Lindholm S, Ploj K, Franck J, Nylander I. Repeated ethanol administration induces short- and long-term changes in enkephalin and dynorphin tissue concentrations in rat brain. Alcohol (2000) 22(3):165-71. doi:10.1016/S0741-8329(00)00118-X
118. D'Addario C, Caputi FF, Rimondini R, Gandolfi O, Del Borrello E, Candeletti S, et al. Different alcohol exposures induce selective alterations on the expression of dynorphin and nociceptin systems related genes in rat brain. Addict Biol (2013) 18(3):425-33. doi:10.1111/j.1369-1600.2011.00326.x
119. Muschamp JW, Carlezon WA Jr. Roles of nucleus accumbens CREB and dynorphin in dysregulation of motivation. Cold Spring Harb Perspect Med (2013) 3(2):a012005. doi:10.1101/cshperspect.a012005
120. Bazov I, Kononenko O, Watanabe H, Kuntic V, Sarkisyan D, Taqi MM, et al. The endogenous opioid system in human alcoholics: molecular adaptations in brain areas involved in cognitive control of addiction. Addict Biol (2013) 18(1):161-9. doi:10.1111/j.1369-1600.2011.00366.x
121. Rassnick S, Heinrichs SC, Britton KT, Koob GF. Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res (1993) 605(1):25-32. doi:10.1016/0006-8993(93)91352-S
122. Rasmussen DD, Mitton DR, Green J, Puchalski S. Chronic daily ethanol and withdrawal: 2. Behavioral changes during prolonged abstinence. Alcohol Clin Exp Res (2001) 25(7):999-1005. doi:10.1111/j.1530-0277.2001.tb02308.x
123. Valdez GR, Sabino V, Koob GF. Increased anxiety-like behavior and ethanol self-administration in dependent rats: reversal via corticotropin-releasing factor-2 receptor activation. Alcohol Clin Exp Res (2004) 28(6):865-72. doi:10.1097/01.ALC.0000128222.29875.40
124. Valdez GR, Zorrilla EP, Roberts AJ, Koob GF. Antagonism of corticotropin-releasing factor attenuates the enhanced responsiveness to stress observed during protracted ethanol abstinence. Alcohol (2003) 29(2):55-60. doi:10.1016/S0741-8329(03)00020-X
125. Valdez GR, Harshberger E. kappa opioid regulation of anxiety-like behavior during acute ethanol withdrawal. Pharmacol Biochem Behav (2012) 102(1):44-7. doi:10.1016/j.pbb.2012.03.019
126. Williams AM, Reis DJ, Powell AS, Neira LJ, Nealey KA, Ziegler CE, et al. The effect of intermittent alcohol vapor or pulsatile heroin on somatic and negative affective indices during spontaneous withdrawal in Wistar rats. Psychopharmacology (2012) 223(1):75-88. doi:10.1007/s00213-012-2691-3
127. Kessler RC, Avenevoli S, Costello EJ, Georgiades K, Green JG, Gruber MJ, et al. Prevalence, persistence, and sociodemographic correlates of DSM-IV disorders in the national comorbidity survey replication adolescent supplement. Arch Gen Psychiatry (2012) 69(4):372-80. doi:10.1001/archgenpsychiatry.2011.160
128. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet (2012) 380(9836):37-43. doi:10.1016/S0140-6736(12)60240-2
129. Cerda M, Sagdeo A, Galea S. Comorbid forms of psychopathology: key patterns and future research directions. Epidemiol Rev (2008) 30:155-77. doi:10.1093/epirev/mxn003
130. Kissler JL, Sirohi S, Reis DJ, Jansen HT, Quock RM, Smith DG, et al. The one-two punch of alcoholism: role of central amygdala dynorphins/kappa-opioid receptors. Biol Psychiatry (2014) 75(10):774-82. doi:10.1016/j.biopsych.2013.03.014
131. Wright JS, Panksepp J. Toward affective circuit-based preclinical models of depression: sensitizing dorsal PAG arousal leads to sustained suppression of positive affect in rats. Neurosci Biobehav Rev (2011) 35(9):1902-15. doi:10.1016/j.neubiorev.2011.08.004
132. Milligan G. Principles: extending the utility of [35S]GTP gamma S binding assays. Trends Pharmacol Sci (2003) 24(2):87-90. doi:10.1016/S0165-6147(02)00027-5
133. Kang-Park M, Kieffer BL, Roberts AJ, Siggins GR, Moore SD. kappa-opioid receptors in the central amygdala regulate ethanol actions at presynaptic GABAergic Sites. J Pharmacol Exp Ther (2013) 346(1):130-7. doi:10.1124/jpet.112.202903
134. Kenny PJ, Chen SA, Kitamura O, Markou A, Koob GF. Conditioned withdrawal drives heroin consumption and decreases reward sensitivity. J Neurosci (2006) 26(22):5894-900. doi:10.1523/JNEUROSCI.0740-06.2006
135. Gillett K, Harshberger E, Valdez GR. Protracted withdrawal from ethanol and enhanced responsiveness stress: Regulation via the dynorphin/kappa opioid receptor system. Alcohol (2013) 47(5):359-65. doi:10.1016/j.alcohol.2013.05.001
136. Goeldner C, Lutz PE, Darcq E, Halter T, Clesse D, Ouagazzal AM, et al. Impaired emotional-like behavior and serotonergic function during protracted abstinence from chronic morphine. Biol Psychiatry (2011) 69(3):236-44. doi:10.1016/j.biopsych.2010.08.021
137. Lutz PE, Reiss D, Ouagazzal AM, Kieffer BL. A history of chronic morphine exposure during adolescence increases despair-like behaviour and strain-dependently promotes sociability in abstinent adult mice. Behav Brain Res (2013) 243:44-52. doi:10.1016/j.bbr.2012.12.049
138. Lutz PE, Pradhan AA, Goeldner C, Kieffer BL. Sequential and opposing alterations of 5-HT(1A) receptor function during withdrawal from chronic morphine. Eur Neuropsychopharmacol (2011) 21(11):835-40. doi:10.1016/j.euroneuro.2011.02.002
139. Lutz PE, Ayranci G, Chu-Sin-Chung P, Matifas A, Koebel P, Filliol D, et al. Distinct mu, delta and kappa opioid receptor mechanisms underlie low sociability and depressive-like behaviors during heroin abstinence. Neuropsychopharmacology (2014) 39(11):2694-705. doi:10.1038/npp.2014.126
140. Belin D, Mar AC, Dalley JW, Robbins TW, Everitt BJ. High impulsivity predicts the switch to compulsive cocaine-taking. Science (2008) 320(5881):1352-5. doi:10.1126/science.1158136
141. Deroche-Gamonet V, Belin D, Piazza PV. Evidence for addiction-like behavior in the rat. Science (2004) 305(5686):1014-7. doi:10.1126/science.1099020
142. Spetea M, Asim MF, Noha S, Wolber G, Schmidhammer H. Current kappa opioid receptor ligands and discovery of a new molecular scaffold as a kappa opioid receptor antagonist using pharmacophore-based virtual screening. Curr Pharm Des (2013) 19(42):7362-72. doi:10.2174/138161281942140105162601
143. Dean AJ, Bell J, Christie MJ, Mattick RP. Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence. Eur Psychiatry (2004) 19(8):510-3. doi:10.1016/j.eurpsy.2004.09.002
144. Rorick-Kehn LM, Witkin JM, Statnick MA, Eberle EL, McKinzie JH, Kahl SD, et al. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology (2014) 77:131-44. doi:10.1016/j.neuropharm.2013.09.021
145. Urbano M, Guerrero M, Rosen H, Roberts E. Antagonists of the kappa opioid receptor. Bioorg Med Chem Lett (2014) 24(9):2021-32. doi:10.1016/j.bmcl.2014.03.040
146. Carroll FI, Carlezon WA Jr. Development of kappa opioid receptor antagonists. J Med Chem (2013) 56(6):2178-95. doi:10.1021/jm301783x
147. Melief EJ, Miyatake M, Carroll FI, Beguin C, Carlezon WA Jr, Cohen BM, et al. Duration of action of a broad range of selective kappa-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation. Mol Pharmacol (2011) 80(5):920-9. doi:10.1124/mol.111.074195
148. Melief EJ, Miyatake M, Bruchas MR, Chavkin C. Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling. Proc Natl Acad Sci U S A (2010) 107(25):11608-13. doi:10.1073/pnas.1000751107
149. Pradhan AA, Smith ML, Kieffer BL, Evans CJ. Ligand-directed signalling within the opioid receptor family. Br J Pharmacol (2012) 167(5):960-9. doi:10.1111/j.1476-5381.2012.02075.x
150. Al-Hasani R, Bruchas MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology (2011) 115(6):1363-81. doi:10.1097/ALN.0b013e318238bba6
151. Schattauer SS, Miyatake M, Shankar H, Zietz C, Levin JR, Liu-Chen LY, et al. Ligand directed signaling differences between rodent and human kappa-opioid receptors. J Biol Chem (2012) 287(50):41595-607. doi:10.1074/jbc. M112.381368
152. Wang SC, Tsou HH, Chung RH, Chang YS, Fang CP, Chen CH, et al. The association of genetic polymorphisms in the kappa-opioid receptor 1 gene with body weight, alcohol use, and withdrawal symptoms in patients with methadone maintenance. J Clin Psychopharmacol (2014) 34(2):205-11. doi:10.1097/JCP.0000000000000082
153. Nielsen DA, Hamon SC, Kosten TR. The kappa-opioid receptor gene as a predictor of response in a cocaine vaccine clinical trial. Psychiatr Genet (2013) 23(6):225-32. doi:10.1097/YPG.0000000000000008
154. Gerra G, Somaini L, Leonardi C, Cortese E, Maremmani I, Manfredini M, et al. Association between gene variants and response to buprenorphine maintenance treatment. Psychiatry Res (2014) 215(1):202-7. doi:10.1016/j.psychres.2013.11.001
155. Zheng MQ, Nabulsi N, Kim SJ, Tomasi G, Lin SF, Mitch C, et al. Synthesis and evaluation of 11C-LY2795050 as a kappa-opioid receptor antagonist radiotracer for PET imaging. J Nucl Med (2013) 54(3):455-63. doi:10.2967/jnumed.112.109512
156. Markou A, Kosten TR, Koob GF. Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology (1998) 18(3):135-74. doi:10.1016/S0893-133X(97)00113-9
157. Hill MN, Hellemans KG, Verma P, Gorzalka BB, Weinberg J. Neurobiology of chronic mild stress: parallels to major depression. Neurosci Biobehav Rev (2012) 36(9):2085-117. doi:10.1016/j.neubiorev.2012.07.001
158. Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology (2005) 52(2):90-110. doi:10.1159/000087097
159. Bambico FR, Belzung C. Novel insights into depression and antidepressants: a synergy between synaptogenesis and neurogenesis? Curr Top Behav Neurosci (2013) 15:243-91. doi:10.1007/7854_2012_234
160. Papp M, Willner P, Muscat R. An animal model of anhedonia: attenuation of sucrose consumption and place preference conditioning by chronic unpredictable mild stress. Psychopharmacology (1991) 104(2):255-9. doi:10.1007/BF02244188
161. Valverde O, Smadja C, Roques BP, Maldonado R. The attenuation of morphine-conditioned place preference following chronic mild stress is reversed by a CCKB receptor antagonist. Psychopharmacology (1997) 131(1):79-85. doi:10.1007/s002130050268
162. Al-Hasani R, McCall JG, Bruchas MR. Exposure to chronic mild stress prevents kappa opioid-mediated reinstatement of cocaine and nicotine place preference. Front Pharmacol (2013) 4:96. doi:10.3389/fphar.2013.00096
163. Lanteri C, Doucet EL, Hernandez Vallejo SJ, Godeheu G, Bobadilla AC, Salomon L, et al. Repeated exposure to MDMA triggers long-term plasticity of noradrenergic and serotonergic neurons. Mol Psychiatry (2014) 19(7):823-33. doi:10.1038/mp.2013.97
164. Tassin JP. Uncoupling between noradrenergic and serotonergic neurons as a molecular basis of stable changes in behavior induced by repeated drugs of abuse. Biochem Pharmacol (2008) 75(1):85-97. doi:10.1016/j.bcp.2007.06.038
165. Pietrzak RH, Naganawa M, Huang Y, Corsi-Travali S, Zheng MQ, Stein MB, et al. Association of in vivo kappa-opioid receptor availability and the transdiagnostic dimensional expression of trauma-related psychopathology. JAMA Psychiatry (2014) 71(11):1262-70. doi:10.1001/jamapsychiatry.2014.1221